Last reviewed · How we verify
mRNA vaccine BNT162b2 (Pfizer)
mRNA vaccine BNT162b2 (Pfizer) is a mRNA vaccine Biologic drug developed by CanSino Biologics Inc.. It is currently in Phase 3 development for COVID-19 prevention in individuals 6 months of age and older, COVID-19 booster vaccination.
BNT162b2 is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection.
BNT162b2 is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection. Used for COVID-19 prevention in individuals 6 months of age and older, COVID-19 booster vaccination.
At a glance
| Generic name | mRNA vaccine BNT162b2 (Pfizer) |
|---|---|
| Sponsor | CanSino Biologics Inc. |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein (S protein) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine delivers lipid nanoparticle-encapsulated mRNA encoding the full-length spike protein of SARS-CoV-2. Upon intramuscular injection, the mRNA is translated by host ribosomes to produce spike protein antigen, which activates both CD8+ T-cell and B-cell mediated immunity. This generates neutralizing antibodies and cellular immunity against the virus.
Approved indications
- COVID-19 prevention in individuals 6 months of age and older
- COVID-19 booster vaccination
Common side effects
- Injection site pain
- Fatigue
- Headache
- Myalgia
- Chills
- Fever
- Lymphadenopathy
Key clinical trials
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients (PHASE2)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- COVID Protection After Transplant-Immunosuppression Reduction (PHASE2)
- COVID-19 Vaccination of Immunodeficient Persons (COVAXID) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mRNA vaccine BNT162b2 (Pfizer) CI brief — competitive landscape report
- mRNA vaccine BNT162b2 (Pfizer) updates RSS · CI watch RSS
- CanSino Biologics Inc. portfolio CI
Frequently asked questions about mRNA vaccine BNT162b2 (Pfizer)
What is mRNA vaccine BNT162b2 (Pfizer)?
How does mRNA vaccine BNT162b2 (Pfizer) work?
What is mRNA vaccine BNT162b2 (Pfizer) used for?
Who makes mRNA vaccine BNT162b2 (Pfizer)?
What drug class is mRNA vaccine BNT162b2 (Pfizer) in?
What development phase is mRNA vaccine BNT162b2 (Pfizer) in?
What are the side effects of mRNA vaccine BNT162b2 (Pfizer)?
What does mRNA vaccine BNT162b2 (Pfizer) target?
Related
- Drug class: All mRNA vaccine drugs
- Target: All drugs targeting SARS-CoV-2 spike protein (S protein)
- Manufacturer: CanSino Biologics Inc. — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for COVID-19 prevention in individuals 6 months of age and older
- Indication: Drugs for COVID-19 booster vaccination